Bank Julius Baer & Co. Ltd Zurich Has $524,000 Holdings in Eli Lilly and Company $LLY

Bank Julius Baer & Co. Ltd Zurich reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 8.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 671,712 shares of the company’s stock after selling 58,498 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich owned approximately 0.07% of Eli Lilly and Company worth $524,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. PNC Financial Services Group Inc. increased its stake in shares of Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after buying an additional 50,002,551 shares during the period. Nuveen LLC acquired a new stake in Eli Lilly and Company in the first quarter worth about $4,613,912,000. Vanguard Group Inc. increased its position in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after purchasing an additional 4,975,395 shares during the period. Assenagon Asset Management S.A. lifted its position in Eli Lilly and Company by 106.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after purchasing an additional 765,010 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in Eli Lilly and Company by 13.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after purchasing an additional 682,203 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $1,058.05 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,066.65. The firm has a fifty day moving average of $855.89 and a 200-day moving average of $787.74. The firm has a market capitalization of $1.00 trillion, a price-to-earnings ratio of 69.15, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the business posted $1.18 EPS. The firm’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 29.35%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on LLY shares. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Morgan Stanley increased their price target on Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. Finally, Leerink Partners upgraded Eli Lilly and Company from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $886.00 to $1,104.00 in a report on Monday, November 10th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,027.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.